Checkpoint inhibitor-induced myocarditis and myasthenia gravis in a recurrent/metastatic thymic carcinoma patient: a case report

BACKGROUND: Pembrolizumab, an immune checkpoint inhibitor (ICI), is an IgG4 antibody that blocks interaction between programmed cell death protein 1 and programmed death-ligand 1. Myocarditis, an immune-related adverse event, has been reported in thymic epithelial tumours. Pembrolizumab has also bee...

Descripción completa

Detalles Bibliográficos
Autores principales: Szuchan, Charles, Elson, Leah, Alley, Evan, Leung, Kevin, Camargo, Antonio Lewis, Elimimian, Elizabeth, Nahleh, Zeina, Sadler, Diego
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Grand Rounds
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319805/
https://www.ncbi.nlm.nih.gov/pubmed/32617460
http://dx.doi.org/10.1093/ehjcr/ytaa051

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319805/
https://www.ncbi.nlm.nih.gov/pubmed/32617460
http://dx.doi.org/10.1093/ehjcr/ytaa051

Ejemplares similares